Special considerations and pitfalls for intracerebral bleeding followed COVID-19 case treated by ECMO

Wael Osman Amer; Hussein Awad El Gharieb; Zakaria Ahmed; Hossam Ibrahim; Ahmed Alanazi; Mostafa Meshref

doi:10.1016/j.hest.2023.06.001

Special considerations and pitfalls for intracerebral bleeding followed COVID-19 case treated by ECMO

Brain Hemorrhages. 2023 Jun 10. doi: 10.1016/j.hest.2023.06.001. Online ahead of print.

Authors

Wael Osman Amer^{1

2}, Hussein Awad El Gharieb^{1

2}, Zakaria Ahmed^{1

2}, Hossam Ibrahim³, Ahmed Alanazi⁴, Mostafa Meshref¹

Affiliations

¹ Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
² Professor of Neurology, Faculty Of Medicine, Al-Azhar University, Cairo, Egypt.
³ King Salman Armed Forces Hospital, Tabuk, Saudi Arabia.
⁴ Training Internal Medicine Resident, King Salman Armed Forces Hospital, Tabuk, Saudi Arabia.

Abstract

COVID-19, or coronavirus infection, is an acute respiratory illness caused by the corona virus that can develop into a life-threatening form of ARDS. Extracorporeal membrane oxygenation (ECMO) is a highly effective treatment for life-threatening instances. One of the many complications associated with ECMO was bleeding. COVID patients are at risk for intracerebral bleeding due to several factors, including the drug's action on ACE2 receptors, leading to hypertension, as well as hypercoagulability, dysregulated immune response, DIC, and the use of anticoagulants.

Keywords: COVID-19; Dysregulated immune response; ECMO; Hypercoagulability; ICB.